Cipla Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/wk0w2o2bakq5lau1gj1s0d2y.pdf

Key Takeaways


U.S. Business: Record Revenue, Regulatory Unlocks

Umang Vohra: "We can safely say that all parts of the product are safe and efficacious and that we believe that there is a natural phenomenon of these products."

Regulatory Pathway: Indore Warning Letter, Goa Reinspection Clock

Umang Vohra: "If Goa -- our thinking is that Goa should be due any time for inspection from starting with quarter 1 of the year because it was inspected in August of 2022. So, on a 2-year clock -- sorry, it should be ready for reinspection starting from a quarter 1 of fiscal year -- of the next fiscal. So therefore, actually, that is -- if that inspection clears, then actually nanopaclitaxel will be ahead of market -- ahead of our estimate if that inspection clears."

India & Branded Markets: Chronic Strength, Distribution Depth


Pipeline & Portfolio: Peptides Arrive, Respiratory Stays Core


Margins & Capital Allocation: Mix-Led Expansion, Cash Deployment Ahead


Strategy & Positioning: Specialty Ambition, Pricing Cycle Realism

Umang Vohra: "Maybe our understanding of this therapy is not -- of therapies is not strong enough to do diligence on these assets."
Umang Vohra: "There is no sale. There is no -- as of this moment, there is no sale, and there hasn't been any discussion or any information or any dialogue over the last at least 2 to 3 months that we are aware of."

Guidance & Commitments

CommitmentSpecificsTimeline
Peptide asset launchFirst peptide asset definitely launched; first generic if approvedQ1 FY25
Peptide launches4 launches planned in FY25 (later clarified as 5)FY25
Advair filingSubmit data from new site to FDAMid-FY25
Advair approvalFDA review of 6–9 months, likely closer to 6 monthsEnd of next fiscal (FY25)
Goa reinspection eligibilityFacility due for reinspection on 2-year clock from Aug 2022 inspectionStarting Q1 next fiscal
Abraxane launchLaunch ahead of estimate if Goa inspection clears; delayed if no inspection or it failsConditional on Goa clearance
U.S. market guidanceManagement will provide a view on the U.S. marketEnd of this quarter (next call)
R&D spendTrend of ~6% of revenue continuingNext couple of years
EBITDA marginFull year trending at higher end of guided rangeFY24 (23–24% range)
India domestic growthTarget higher than market growth, expanding into Tier 2–6Next year

Key Metrics

MetricQ3 FY24
Revenue₹6,544 cr, +14% YoY
EBITDA margin26.3%, does not include other income
Gross margin after material cost66.3%, +90 bps YoY
Profit after tax₹1,049 cr, 16% of sales
Effective tax rate27.5%, constant
R&D investment₹400 cr, 6.1% of revenue, +10% YoY
Total expenses (employee + other)₹2,621 cr, flat sequentially
Cash and equivalents₹7,591 cr
Gross debt₹449 cr, lease liabilities and working capital facilities only; all long-term loans repaid including ZAR 72 cr term debt in South Africa
Return on invested capital~29%, trailing 12 months
One-India business growth+12% YoY
Chronic portfolio growth+13% vs IPM growth of 11% (IQVIA MAT December '23)
Chronic therapy share60.3%, +115 bps YoY
North America quarterly revenue$230 million, all-time high, +18% YoY, 15th consecutive quarter of YoY growth
Lanreotide market share20%
SAGA growth ex-QCIL+35% YoY in USD terms
South Africa prescription secondary growth+7% vs market growth of 2% (IQVIA MAT November '23)
Branded prescription brands >₹100 cr20 brands (IQVIA MAT December '23)
Trade generics brands >₹50 cr8 brands
Cipla Health anchor brands >₹100 cr5 brands, trailing 12 months
Full-year EBITDA margin guidanceTrending at higher end of 23% to 24% guided range
U.S. generic price compression bandCurrently in the 4% to 6% range
CapEx typical annual range₹1,000 to ₹1,500 cr
Loss on sale of QCIL~₹18 cr, booked in other income
Advair estimated net price~$30 per inhaler